ArticleStem cell research & therapy2011
Induced pluripotent stem cells from GMP-grade hematopoietic progenitor cells and mononuclear myeloid cells.
Article in Stem cell research & therapy, 2011. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 18 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
18 citing papers in PubMed, 39 citations in OpenAlex.
- Construction of liver organoid models by hepatobiliary differentiation from human induced pluripotent stem cells: state of the art, challenges and improving strategies.Stem cell research & therapy · 2026Review
- Generation of a bank of clinical-grade, HLA-homozygous iPSC lines with high coverage of the Spanish population.Stem cell research & therapy · 2023Article
- Chimpanzee and pig-tailed macaque iPSCs: Improved culture and generation of primate cross-species embryos.Cell reports · 2022Article
- Tissue-Restricted Stem Cells as Starting Cell Source for Efficient Generation of Pluripotent Stem Cells: An Overview.Advances in experimental medicine and biology · 2022Review
- An Overview on Promising Somatic Cell Sources Utilized for the Efficient Generation of Induced Pluripotent Stem Cells.Stem cell reviews and reports · 2021Review
- A scalable solution for isolating human multipotent clinical-grade neural stem cells from ES precursors.Stem cell research & therapy · 2019Article
- Induced Pluripotent Stem Cell Generation from Blood Cells Using Sendai Virus and Centrifugation.Journal of visualized experiments : JoVE · 2016Article
- Recent developments in ex vivo platelet production.Cytotechnology · 2016Review
- Tumor-Free Transplantation of Patient-Derived Induced Pluripotent Stem Cell Progeny for Customized Islet Regeneration.Stem cells translational medicine · 2016Article
- Generation of human iPSCs from cells of fibroblastic and epithelial origin by means of the oriP/EBNA-1 episomal reprogramming system.Stem cell research & therapy · 2015Article
- Induced pluripotent stem cells in hematology: current and future applications.Blood cancer journal · 2014Review
- Concise review: pluripotent stem cell-based regenerative applications for failing β-cell function.Stem cells translational medicine · 2014Review
- The potential of cell-based therapy for diabetes and diabetes-related vascular complications.Current diabetes reports · 2014Review
- The 3R principle: advancing clinical application of human pluripotent stem cells.Stem cell research & therapy · 2013Review
- The multi-differentiation potential of peripheral blood mononuclear cells.Stem cell research & therapy · 2012Review
- Transgene-free disease-specific induced pluripotent stem cells from patients with type 1 and type 2 diabetes.Stem cells translational medicine · 2012Article
- Derivation of autism spectrum disorder-specific induced pluripotent stem cells from peripheral blood mononuclear cells.Neuroscience letters · 2012Article
- Derivation of Sendai-Virus-Reprogrammed Human iPSCs-Neuronal Precursors:Cell transplantationArticle
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors at 1 institution in 1 country.
Funding
Abstract
introductionThe induced pluripotent stem cell (iPSC) technology allows generation of patient-specific pluripotent stem cells, thereby providing a novel cell-therapy platform for severe degenerative diseases. One of the key issues for clinical-grade iPSC derivation is the accessibility of donor cells used for reprogramming.
methodsWe examined the feasibility of reprogramming mobilized GMP-grade hematopoietic progenitor cells (HPCs) and peripheral blood mononuclear cells (PBMCs) and tested the pluripotency of derived iPS clones.
resultsEctopic expression of OCT4, SOX2, KLF4, and c-MYC in HPCs and PBMCs resulted in rapid iPSC derivation. Long-term time-lapse imaging revealed efficient iPSC growth under serum- and feeder-free conditions with frequent mitotic events. HPC- and PBMC-derived iPS cells expressed pluripotency-associated markers, including SSEA-4, TRA-1-60, and NANOG. The global gene-expression profiles demonstrated the induction of endogenous pluripotent genes, such as LIN28, TERT, DPPA4, and PODXL, in derived iPSCs. iPSC clones from blood and other cell sources showed similar ultrastructural morphologies and genome-wide gene-expression profiles. On spontaneous and guided differentiation, HPC- and PBMC-derived iPSCs were differentiated into cells of three germ layers, including insulin-producing cells through endodermal lineage, verifying the pluripotency of the blood-derived iPSC clones.
conclusionsBecause the use of blood cells allows minimally invasive tissue procurement under GMP conditions and rapid cellular reprogramming, mobilized HPCs and unmobilized PBMCs would be ideal somatic cell sources for clinical-grade iPSC derivation, especially from diabetes patients complicated by slow-healing wounds.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.